Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaft, Jamie E., Oezkan, Filiz, Kris, Mark G., Bunn, Paul A., Wistuba, Ignacio I., Kwiatkowski, David J., Owen, Dwight H., Tang, Yan, Johnson, Bruce E., Lee, Jay M., Lozanski, Gerard, Pietrzak, Maciej, Seweryn, Michal, Byun, Woo Yul, Schulze, Katja, Nicholas, Alan, Johnson, Ann, Grindheim, Jessica, Hilz, Stephanie, Shames, David S., Rivard, Chris, Toloza, Eric, Haura, Eric B., McNamee, Ciaran J., Patterson, G. Alexander, Waqar, Saiama N., Rusch, Valerie W., Carbone, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556329/
https://www.ncbi.nlm.nih.gov/pubmed/36097216
http://dx.doi.org/10.1038/s41591-022-01962-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556329/
https://www.ncbi.nlm.nih.gov/pubmed/36097216
http://dx.doi.org/10.1038/s41591-022-01962-5

Ejemplares similares